Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
UC-MSC Infusion for HBV-Related ACLF
NCT02812121Phase 2Unknown
- Sponsor
- Sun Yat-sen University
- Start
- Jun 2016
- Primary completion
- Jun 2017
01
Overview
Phase 2, randomised, open-label trial in acute-on-chronic liver failure (ACLF) (3 arms), sponsored by Sun Yat-sen University. Primary endpoints: Incidence of adverse reactions at 52 weeks and Overall Survival at 52 weeks. Status: unknown.
02
Conditions
acute-on-chronic liver failure (ACLF)
Beyond the preview
Go deeper on NCT02812121.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02812121.